Financing channel feed – Endpoints News

Financing channel feed

A booming market propels China CRO to a $100M raise. Is an IPO next?

5 years ago

The biotech IPO train keeps chugging, as Virios prices $30M public debut

5 years ago

AbbVie's Covid-19 antibody partner wraps $221M Hong Kong IPO

5 years ago

Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year

5 years ago

BioAtla heads for Nasdaq on Wednesday following $189M IPO, going public with its pH-detecting cancer treatments

5 years ago

After leaving Wall Street to launch a gene therapy upstart, Rachel McMinn nabs $115M to drive her first candidate to the clinic

5 years ago

After reeling back a gene therapy from Sanofi, a North Carolina upstart bags enough money to do something about it

5 years ago

Updated: Neuron23 launches with $113M financing and eyes dead set on Denali and Biogen

5 years ago

Out of CRISPR pioneer David Liu's lab comes a small molecule play targeting exosites — and it's raised a modest $25M to push toward clinic

5 years ago

Allogene, Overland plot speedy Asia play for off-the-shelf CAR-T with $117M joint venture

5 years ago

Sean Harper and Beth Seidenberg add $500M to their new VC, betting on the LA biotech ecosystem

5 years ago

Sanofi, Novo back a small biotech that's neck and neck with Pfizer to develop a Group B streptococcus vaccine

5 years ago

CRISPR upstart ticks off another box on the IPO prep list as RA, SVB Leerink step in on a mega-raise

5 years ago

After scoring big Pfizer buyout, a Therachon co-founder turns once again to dwarfism with $24M Series A

5 years ago

Rani nabs $69M Series E for its stab at a robotic pill to replace injectable drugs

5 years ago

Marrying precision med and AI, Groupon co-founder Eric Lefkofsky takes total haul for his analytics firm over the $1B line

5 years ago

2020's IPO party continues with four new Nasdaq entrants, including Covillionaire Carl Hansen's AbCellera

5 years ago

Faze Medicines launches with $81M Series A, Alnylam vet heading science in play at biomolecular condensates

5 years ago

RA Capital backs Oxford spinout PepGen with a $45M Series A, seeking to treat Duchenne and other similar diseases

5 years ago

Novo and Abingworth back a $95M Series B for Reneo Pharmaceuticals, which aims to treat diseases of the mitochondria

5 years ago

Pear Therapeutics nabs $80M Series D to commercialize three digital therapeutics

5 years ago

Barely two months after unveiling a new breed of radiopharmaceuticals, RayzeBio brings total haul to $150M

5 years ago

Vigil Neuroscience launches with a $50M Series A and two former Amgen neuroscience candidates

5 years ago

Driven by Covid-19 fever, Forbion notes investor interest in vaccines and new therapies as part of $557M fund

5 years ago

First page Previous page 85 86 878889 90 91 Next page Last page